Evidence map›Paper›PMID 42035486›Full record

ReviewNano letters2026

Dual-Stimuli Injectable Platforms for Localized Breast Cancer Therapy.

Celia Nieto, Álvaro González-Garcinuño, Antonio Tabernero, Eva M Martín Del Valle

Abstract readReview
In one paragraph

Review in Nano letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Celia NietoDepartment of Chemical Engineering, University of Salamanca, Plaza de los Caídos s/n, 37001 Salamanca, Spain.
Álvaro González-GarcinuñoDepartment of Chemical Engineering, University of Salamanca, Plaza de los Caídos s/n, 37001 Salamanca, Spain.ORCID 0000-0003-0013-9953
Antonio TaberneroDepartment of Chemical Engineering, University of Salamanca, Plaza de los Caídos s/n, 37001 Salamanca, Spain.
Eva M Martín Del ValleDepartment of Chemical Engineering, University of Salamanca, Plaza de los Caídos s/n, 37001 Salamanca, Spain.ORCID 0000-0003-3506-2546

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Locoregional breast cancer recurrence remains a significant therapeutic challenge, largely driven by limited drug selectivity and toxicity to surrounding healthy tissues. This Mini-Review examines the emerging potential of pH- and temperature-responsive formulations as injectable drug delivery systems designed to achieve preferential targeting of malignant cells. A range of advanced platforms─from smart hydrogels to hybrid constructs such as pH-sensitive liposomes embedded within thermoresponsive hydrogel matrices─are discussed, with emphasis on key design principles and synthesis strategies enabling environmental responsiveness. Among the technologies reviewed, liposome-in-hydrogel hybrid systems─still largely unexplored in breast cancer therapy─stand out for their capacity to enhance encapsulation of lipophilic therapeutics, improve formulation stability, streamline manufacturing, and provide sustained, spatially controlled drug release. Finally, critical physicochemical, mechanical, and biological characterization studies that are needed to rigorously evaluate the translational and clinical potential of these materials for the treatment of locoregional recurrent breast cancer are outlined.

Indexed as

Antineoplastic AgentsBreast NeoplasmsDrug Delivery SystemsHydrogelsNeoplasm Recurrence, LocalAnimalsDelayed-Action PreparationsFemaleHumansHydrogen-Ion ConcentrationInjectionsLiposomesTemperatureAntineoplastic AgentsDelayed-Action PreparationsHydrogelsLiposomesbreast cancerdrug delivery systeminjectable hydrogelliposomespH-responsivethermoresponsive

Identifiers

PMID42035486
PMCPMC13154346

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.